Here is the reference I was talking about:
Thanks. I was able to get the link (2005) from the text you posted, I think.
link.springer.com
Unfortunately the other link you posted seems to have a security glitch, and my browser advised against following it.
ALSO THERE IS ZERO PROOF INSULIN THERAPY PRESERVES BETA CELLS,
Yes, that was also in the study I found. Although as I understand it UKPDS showed that starting insulin early did not slow down autoimmune destruction of beta cells in LADA vs oral meds, but the progression to insulin in LADA is generally faster than classic T2.
I found this very interesting from the editorial/commentary you posted
Does LADA exist?
Is LADA a distinct disease entity or one end of a spectrum of immune-mediated diabetes? Given that it is logically impossible to distinguish between two conditions when one (LADA) is defined solely by the characteristics it shares with the other (type 1 diabetes), this easily becomes an exercise in semantics. There is currently no reason to assume that the underlying aetiology is any different. A simple example may help. Jack Spratt is a lean middle-aged jogger and Humphrey Dumpty is his indolent overweight neighbour. Both suffer from progressive beta cell failure and have high levels of GAD antibodies. Jack Spratt is lean and insulin-sensitive, so his blood glucose does not begin to rise until he approaches end-stage beta cell failure. He needs insulin straight away. Humphrey Dumpty, in contrast, is relatively insulin-resistant. He can still make useful amounts of insulin when diabetes is detected. He goes on a diet, enrols at a gym, and starts treatment with an insulin secretagogue, an insulin sensitiser, or both. This corrects the short-term imbalance between insulin secretion and sensitivity and a year or more will pass before he too requires insulin. Jack is considered to have late-onset type 1 diabetes, whereas Humphrey will be said to have LADA, but they differ only in sensitivity to insulin, and the underlying process of beta cell failure is exactly the same. At our present level of understanding, it makes more sense to regard autoimmune diabetes as a continuum, and to devote less time and energy to drawing artificial distinctions between its various manifestations.
And the summary
In summary, the grounds for designating LADA as a distinct aetiological entity are insubstantial, its epidemiology is plagued by methodological problems, and the clinical value of diagnosing it has not been demonstrated.
Which backs up the general feedback from members that many Drs in the period since this was written have moved away from using the term LADA, and no longer find it helpful.
I guess the sharp end, at least in the UK, is really that a diagnosis with T1 (of which LADA when used is generally seen to be a subset) gives you access to various course, and types of therapy like insulin pump, that you can’t get access to if you have T2.